SABS

SAB Biotherapeutics, Inc. - Common Stock (SABS)

About SAB Biotherapeutics, Inc. - Common Stock (SABS)

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.

Details

Daily high
$1.79
Daily low
$1.72
Price at open
$1.78
52 Week High
$5.01
52 Week Low
$1.00
Market cap
16.6M
Dividend yield
0.00%
Volume
11,931
Avg. volume
24,313
P/E ratio
-.48

SAB Biotherapeutics, Inc. - Common Stock News

Details

Daily high
$1.79
Daily low
$1.72
Price at open
$1.78
52 Week High
$5.01
52 Week Low
$1.00
Market cap
16.6M
Dividend yield
0.00%
Volume
11,931
Avg. volume
24,313
P/E ratio
-.48